News and Activities
Hot Off The Press.
Press Releases
Proteocyte Reaches Regulatory Approval Milestone with ISO 15189 Accreditation
Toronto, ON; March 17, 2022 - Proteocyte AI, a company dedicated to producing a range of technological solutions that predict a patient's risk of developing oral cancer, has reached an important milestone in the regulatory process for Straticyte™, its first commercial offering. The company...
Proteocyte Announces Mark Hammar as new CEO
Toronto, ON; January 19, 2022 - Proteocyte AI, a company dedicated to producing a range of technological solutions that predict a patient's risk of developing oral cancer, is pleased to announce the appointment of Mark Hammar as Chief Executive Officer, effective immediately. Mr. Hammar is taking...
Proteocyte Selects Medlior as Health Outcomes Research Provider
MaRS Discovery District, Toronto, ON; December 1, 2021 - Proteocyte AI is pleased to announce its formal engagement with Medlior, a health outcomes research provider based in Calgary, Alberta. Proteocyte will rely on Medlior's team of diverse subject matter experts to bring scientific expertise,...
Proteocyte Completes Successful Financing Round of $1.1 Million
MaRS Discovery District, Toronto, ON; August 4, 2021 - Proteocyte AI, a company dedicated to producing a range of technological solutions that predict a patient's risk of developing oral cancer, is pleased to announce it has recently completed its latest round of convertible debenture financing in...